Endonovo Therapeutics (OTCQB: ENDV) is an innovative biotechnology company developing a bioelectronic approach to regenerative medicine.
Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies.
Our Mission
Endonovo means to renew from within. Our mission is to save lives by treating and preventing vital organ failure.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.